Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls.
Karl
K
Csaky
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000209:etiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000276:immunology; D005584:Fovea Centralis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D008222:Lymphokines / Q000037:antagonists & inhibitors* / Q000276:immunology; D008268:Macular Degeneration / Q000150:complications / Q000628:therapy*; D009841:Oligonucleotides / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000911:Antibodies, Monoclonal; D016228:Endothelial Growth Factors; D007140:Immunoglobulin Fab Fragments; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D009841:Oligonucleotides; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C430291:NX1838